Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma

Thyroid

Volumn 20, Issue 3, 2010, Pages 281-286

  Yalcin, Murat ^a,b   Bharali, Dhruba J ^a   Dyskin, Evgeny ^a   Dier, Emmy ^a   Lansing, Lawrence ^a   Mousa, Shaymaa S ^a   Davis, Faith B ^c   Davis, Paul J ^c,d   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ULUDAG UNIVERSITY   (Turkey)

^c ORDWAY RESEARCH INSTITUTE   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NANOPARTICLE; TETRAIODOTHYROACETIC ACID; TETRAIODOTHYROACETIC ACID NANOPARTICLE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELLULAR DISTRIBUTION; CHORIOALLANTOIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROID FOLLICULAR CARCINOMA; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; WEIGHT GAIN; XENOGRAFT;

ADENOCARCINOMA, FOLLICULAR; ANALYSIS OF VARIANCE; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DRUG DELIVERY SYSTEMS; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; THYROID GLAND; THYROXINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77649308057     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.0249     Document Type: Article

References (24)

1. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306.
2. Lin HY, Tang HY, Shih A, Keating T, Cao G, Davis PJ, Davis FB 2007 Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroid 72:180-187.
3. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S, Davis PJ 2005 Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146:2864-2871.
4. Davis FB, Mousa SA, O'Connor L, Mohamed S, Lin HY, Cao HJ, Davis PJ 2004 Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 94:1500-1506.
5. Mousa SA, O'Connor L, Davis FB, Davis PJ 2006 Proangiogenesis action of the thyroid hormone analog 3, 5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology 147:1602- 1607.
6. Davis FB, Tang HY, Shih A, Keating T, Lansing L, Hercbergs A, Fenstermaker RA, Mousa A, Mousa SA, Davis PJ, Lin HY 2006 Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res 66:7270-7275.
7. Moreno M, de Lange P, Lombardi A, Silvestri E, Lanni A, Goglia F 2008. Metabolic effects of thyroid hormone derivatives. Thyroid 18:239-253.
8. Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, Yalcin M, Aljada A, Dyskin E, Davis FB, Lin HY, Davis PJ 2008 Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 11:183-190.
9. Cody V, Davis PJ, Davis FB 2007 Molecular modeling of the thyroid hormone interactions with alphavbeta3 integrin. Steroids 72:165-170.
10. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW 2000 Ligand binding to integrins. J Biol Chem 275:21785-21788.
11. Masson-Gadais B, Houle F, Laferriere J, Huot J 2003 Integrin avb3, requirement for VEGFR2-mediated activation of SAPK2=p38 and Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones 8:37-52.
12. Sahni A, Francis CW 2004 Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires alphavbeta3. Blood 104:3635-3641.
13. Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA 2008 Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis 11:269-276.
14. Jeffery H, Davis SS, Ohagan DT 1991 The preparation and characterization of poly (lactide-co-glycolide) microparticles. 1. Oil-in-water emulsion solvent evaporation. Int J Pharm 77:169-175.
15. Song CX, Labhasetwar V, Qu X, Humphery WR, Shebuski RJ, Levi RJ 1997 Formulation and characterization of bio-degradable nanoparticles for intravascular local drug delivery. J Control Release 43:197-212.
16. Hermanson G 1996 Bio conjugate Technique. Academic press, California, pp. 617-618.
17. Bergstrom K, Holmberg A, Safrani AS, Hoffman MJ, Edgell A, Kozlowski BA, Hovanes JM, Harris JM 1992 Reduction of fibrinogen adsorption on PEG coated polystyrene surfaces. J Biomed Mater Res 26:779-790.
18. Mousa SS, Mousa SA 2006 Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancer. J Cell Biochem 97:1370-1378.
19. Tang HY, Lin HY, Zhang S, Davis FB, Davis PJ 2004 Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 145:3265-3272.
20. Mousa SA, O'Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ 2005 The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharm 46:356-360.
21. Mousa SA, Davis FB, Mohamed S, Davis PJ, Feng X 2006 Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model. Int Angiol 25:407-413.
22. Theodossiou C, Skrepnik N, Robert EG, Prasad C, Axelrad TW, Schapira DV, Hunt JD 1999 Propylthiouracil-induced hypothyroidism reduces xenograft tumor growth in athymic nude mice. Cancer 86:1596-1601.
23. Bergers G, Hanahan D 2008 Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603.
24. Chiarugi P, Giannoni E 2008 Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol 76:1352-1364.